MRK Quote, Financials, Valuation and Earnings

Cidara Therapeutics, Inc. has a net margin of 33.68% compared to Merck & Co., Inc.'s net margin of -30201.66%. Merck & Co., Inc.'s return on equity of 39.63% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Merck & Co., Inc. has a consensus price target of $110.62, signalling upside risk potential of 1.86%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.05%. Given that Merck & Co., Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Merck & Co., Inc. is more attractive than Cidara Therapeutics, Inc..

Merck & Co., Inc. has a beta of 0.291, which suggesting that the stock is 70.859% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.523, suggesting its more volatile than the S&P 500 by 52.269%.

Merck & Co., Inc. has a quarterly dividend of $0.85 per share corresponding to a yield of 3.02%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & Co., Inc. pays 46.32% of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $17.2B, which are larger than Cidara Therapeutics, Inc. quarterly revenues of --. Merck & Co., Inc.'s net income of $5.8B is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 14.37x while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.28x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of 33.68% compared to Merck & Co., Inc.'s net margin of 39.21%. Merck & Co., Inc.'s return on equity of 39.63% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Merck & Co., Inc. has a consensus price target of $110.62, signalling upside risk potential of 1.86%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.57 which suggests that it could grow by 6.61%. Given that Gilead Sciences, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Gilead Sciences, Inc. is more attractive than Merck & Co., Inc..

Merck & Co., Inc. has a beta of 0.291, which suggesting that the stock is 70.859% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.568%.

Merck & Co., Inc. has a quarterly dividend of $0.85 per share corresponding to a yield of 3.02%. Gilead Sciences, Inc. offers a yield of 2.54% to investors and pays a quarterly dividend of $0.79 per share. Merck & Co., Inc. pays 46.32% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Merck & Co., Inc. quarterly revenues are $17.2B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. Merck & Co., Inc.'s net income of $5.8B is higher than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 14.37x while Gilead Sciences, Inc.'s PE ratio is 19.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.28x versus 5.38x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 33.68% compared to Merck & Co., Inc.'s net margin of -19.69%. Merck & Co., Inc.'s return on equity of 39.63% beat Moderna, Inc.'s return on equity of -30.18%.

Merck & Co., Inc. has a consensus price target of $110.62, signalling upside risk potential of 1.86%. On the other hand Moderna, Inc. has an analysts' consensus of $36.90 which suggests that it could grow by 2.81%. Given that Moderna, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Moderna, Inc. is more attractive than Merck & Co., Inc..

Merck & Co., Inc. has a beta of 0.291, which suggesting that the stock is 70.859% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Merck & Co., Inc. has a quarterly dividend of $0.85 per share corresponding to a yield of 3.02%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & Co., Inc. pays 46.32% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $17.2B, which are larger than Moderna, Inc. quarterly revenues of $1B. Merck & Co., Inc.'s net income of $5.8B is higher than Moderna, Inc.'s net income of -$200M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 14.37x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.28x versus 6.23x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 33.68% compared to Merck & Co., Inc.'s net margin of 38.89%. Merck & Co., Inc.'s return on equity of 39.63% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Merck & Co., Inc. has a consensus price target of $110.62, signalling upside risk potential of 1.86%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $804.96 which suggests that it could fall by -0.9%. Given that Merck & Co., Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Merck & Co., Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Merck & Co., Inc. has a beta of 0.291, which suggesting that the stock is 70.859% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Merck & Co., Inc. has a quarterly dividend of $0.85 per share corresponding to a yield of 3.02%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.43% to investors and pays a quarterly dividend of $0.88 per share. Merck & Co., Inc. pays 46.32% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $17.2B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Merck & Co., Inc.'s net income of $5.8B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 14.37x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.28x versus 6.28x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.